Publications by authors named "Maya McKeown"
Article Synopsis
- - The study investigates the prevalence of phase 3 clinical trials for neurologic drugs that started without a positive phase 2 trial, finding that 46% of such trials bypassed or overrode phase 2 outcomes, which could affect the risk/benefit ratio of these trials.
- - Using data from 2011-2021, the researchers analyzed 1,188 phase 3 trials, concluding that those relying on phase 2 bypass/override had a significantly lower chance of achieving positive primary outcomes, indicating potential issues with efficacy.
- - The study also found that the practice of bypassing phase 2 trials was not significantly linked to industry funding or testing already approved interventions, suggesting that other factors may drive this trend in neurolog
